Overview Surufatinib Hepatic Impairment Study Status: Completed Trial end date: 2021-10-11 Target enrollment: Participant gender: Summary An open-label, multicenter, single-dose, single-period, sequential study to determine the effect of hepatic impairment on the PK of surufatinib. Phase: Phase 1 Details Lead Sponsor: Hutchison Medipharma Limited